Guardion Health Sciences, Inc. Announces 1-for-50 Reverse Stock Split Effective on Pre-Market Opening on January 9, 2023
06 Gennaio 2023 - 10:15PM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(NASDAQ: GHSI) announced today that it will effect a 1-for-50
reverse split of its common stock effective as of 4:01 p.m. Eastern
Time on January 6, 2023. Commencing with the opening of trading on
the Nasdaq Capital Market on January 9, 2023, the Company’s common
stock will trade on a post-split basis under the same symbol GHSI.
The reverse stock split was approved by the Company’s stockholders
at the special meeting of stockholders held on January 5, 2023,
with the final ratio determined by the Company’s Board of
Directors.
As a result of the reverse stock split, the
CUSIP number for the Company’s common stock will be changed to
40145Q500, and every 50 shares of issued and outstanding common
stock will be exchanged for 1 share of common stock, with any
fractional shares being rounded up to the next higher whole share.
Immediately after the reverse stock split becomes effective, the
Company will have approximately 1,232,016 shares of common stock
issued and outstanding
The reverse stock split is primarily intended to
bring the Company into compliance with Nasdaq’s minimum bid price
requirement. However, there can be no assurances that the Company
will be able to remain in compliance with the minimum bid price
requirement over time, or that it will be successful in maintaining
compliance with any of the other Nasdaq continued listing
requirements.
Additional information concerning the reverse
stock split can be found in the Company’s definitive proxy
statement filed with the Securities and Exchange
Commission on December 12, 2022.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI),
is a clinical nutrition company that offers a portfolio of
science-based, clinically supported products designed to support
the health needs of consumers, healthcare professionals and
providers and their patients. The Company’s combination of
expertise and scientifically supported products is the foundation
of Guardion’s growing position within the clinical nutrition
marketplace. Information and risk factors with respect to Guardion
and its business may be obtained in the Company’s filings with the
SEC at www.sec.gov.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These
forward-looking statements contain information about our
expectations, beliefs, plans or intentions regarding our product
development and commercialization efforts, research and development
efforts, business, financial condition, results of operations,
strategies or prospects, and other similar matters. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans,” “hopes” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing.
These statements are based on management’s
current expectations and assumptions about future events, which are
inherently subject to uncertainties, risks and changes in
circumstances that are difficult to predict, and involve unknown
risks and uncertainties that may individually or materially impact
the matters discussed herein for a variety of reasons that are
outside the control of the Company, including, but not limited to,
the Company’s ability to raise sufficient financing to implement
its business plan, the impact of the Company’s exploration of
strategic alternatives, the integration of new management team
members, the implementation of new financial, management,
accounting and business software systems, the integration of
possible acquisition targets, the impact of the Covid-19 pandemic,
supply chain disruptions, inflation and a potential recession on
the Company’s business, operations and the economy in general, the
Company’s ability to successfully develop and commercialize its
proprietary products and technologies, and the Company’s ability to
maintain compliance with Nasdaq’s listing requirements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, as actual results
could differ materially from those described in the forward-looking
statements contained herein. Readers are urged to read the risk
factors set forth in the Company’s filings with the SEC, which are
available at the SEC’s website (www.sec.gov). The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:CORE IRScott
Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Grafico Azioni Guardion Health Sciences (NASDAQ:GHSI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Guardion Health Sciences (NASDAQ:GHSI)
Storico
Da Giu 2023 a Giu 2024